Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)

This extension will employ the same medications, measurements, guidelines for anti-VEGF injections and safeguards as in protocol 0002. In combination with protocol 0002, it will provide a total of 12 months of therapy with carbidopa-levodopa.

Inclusion criteria

• Completion of Protocol 002.
• A diagnosis of AMd with choroidal neovascularization (CNV) in 1 eye.
• Normal or Dry AMD of any grade in the second eye.
• Age 50-85 years.
• Willingness to maintain AREDS vitamin Supplements throughout the study, or remain off of these supplements for the duration of the study, if not taking them prior to the study.
• Informed consent at visit 1, which is also Visit 5 of study 002.

Exclusion criteria

• Any current use of L-DOPA containing medication or dopamine agonist medication, or any planned use of any of these agents, except for study medication, during the study;
• Concurrent use of monoamine oxidase (MAO) inhibitors;
• Any eye condition, disease, or history of trauma in either eye, which can impair vision, except cataract or cataract surgery;
• BCVA worse than 20/60 in the better eye;
• Wet AMD in the second eye;
• Neurologic conditions which can impair vision;
• Parkinson's Disease;
• Significant orthostatic hypotension, defined as a drop in systolic blood pressure, immediately upon changing from the supine to standing position, of >19 mmHg, or a symptomatic drop in systolic blood pressure, immediately upon changing from the supine to standing position;
• Significant ECG abnormalities, as judged by the Investigator;
• Estimated glomerular filtration rate (eGFR) <20 ml/min;
• Liver enzymes >3 X the upper limit of normal;
• HbA1C >9.0;
• Any other significant lab abnormalities, as judged by the Investigator.
• Women of childbearing potential;
• Known retinal hemorrhage;
• Subjects who are not fluent in English.